611 related articles for article (PubMed ID: 32083997)
1. State-of-the-Art Strategies for Targeting
Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
[TBL] [Abstract][Full Text] [Related]
2. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
3. Progresses Toward Precision Medicine in
Belli C; Anand S; Gainor JF; Penault-Llorca F; Subbiah V; Drilon A; Andrè F; Curigliano G
Clin Cancer Res; 2020 Dec; 26(23):6102-6111. PubMed ID: 32665298
[No Abstract] [Full Text] [Related]
4. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
5. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Drilon A; Hu ZI; Lai GGY; Tan DSW
Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
[TBL] [Abstract][Full Text] [Related]
6. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract][Full Text] [Related]
7. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
8. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
9. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
10. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
11. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
12. Precious Gene: The Application of RET-Altered Inhibitors.
Gou Q; Gan X; Li L; Gou Q; Zhang T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
14. Targeting RET alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract][Full Text] [Related]
15. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
17. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
18. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
20. The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D; Santoro M; Schlumberger M
Nat Rev Endocrinol; 2021 May; 17(5):296-306. PubMed ID: 33603219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
